Looks like Forbes chose to plug in some numbers and spit out a report. Nothing about pipeline which is the reason we are all here - I think.
If 4430 is going to be of any help in offsetting medical resources taken up by seasonal flu, they should be ramping up production now - JS said the 3-6 month timeline for RNA treatment production like Remdesivir was about right and they only had enough for 4430 trials in Brazil.
So far JS has been fairly accurate about the expected news flow dealing with pre-COVID pipeline including the surprise early auth for Orladeyo. Still, it's difficult not to be excited about getting news for 4430 at some point over the summer.